<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8142">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03000946</url>
  </required_header>
  <id_info>
    <org_study_id>P150915</org_study_id>
    <nct_id>NCT03000946</nct_id>
  </id_info>
  <brief_title>Prevention of Postoperative Pancreatic Fistulaby Somatostatin</brief_title>
  <acronym>PREFIPS</acronym>
  <official_title>Prevention of Postoperative Pancreatic Fistula by SOMATOSTATIN Compared to OCTREOTIDE: Prospective, Randomized, Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether somatostatin is more effective that
      octreotide in the prevention of post-pancreatectomy pancreatic fistula
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prevention of pancreatic fistula remains a major challenge for surgeons, and various
      technical and pharmacological intervention have been investigated, with conflicting results.

      Despite several prospective studies, and metaanalyses, the prophylactic role on pancreatic
      fistula of octreotide, remains controversial, even if recommended for routine use in
      patients undergoing pancreatic resection.

      In view of recent result, the investigators can hypothesize that higher affinity for
      somatostatin-receptor lead to stronger pancreatic exocrine secretion inhibition, and better
      pancreatic fistula prevention.

      Consequently, continuous intravenous infusion of somatostatin-14, the natural peptide
      hormone, associated with 10 to 50 time stronger affinity with all somatostatin receptor,
      will be associated with a improved pancreatic fistula prevention compared to octreotide.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>≥ grade B or C postoperative pancreatic fistula as defined by the ISGPF (International Study Group on Pancreatic Fistula) classification</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>≥grade 3 pancreatic complication rates (fistula, leak, and abscess)</measure>
    <time_frame>60 days</time_frame>
    <description>as defined by the MSKCC surgical secondary events system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall pancreatic fistula rate (grade A,B and C)</measure>
    <time_frame>90 days</time_frame>
    <description>ISPGF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall complication rate (grade 1 to 5)</measure>
    <time_frame>90 days</time_frame>
    <description>according to Clavien -Dindo classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe complication rate (grade 3 to 5)</measure>
    <time_frame>90 days</time_frame>
    <description>according to Clavien -Dindo classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality (grade 5)</measure>
    <time_frame>90 days</time_frame>
    <description>according to Clavien -Dindo classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall duration of drainage</measure>
    <time_frame>90 days</time_frame>
    <description>required in patients who develop pancreatic complications (date pancreatic complication identified - date drain removed)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall length of stay</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-admission rate</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost effectiveness</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fistula according to possible new definition of the ISGPF group</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">654</enrollment>
  <condition>Pancreatic Surgery</condition>
  <arm_group>
    <arm_group_label>Somatostatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous intravenous infusion of somatostatin-14, 6 mg per day during 6.5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Octreotide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous octreotide 100 μg 3 times a day for 6.5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatostatin</intervention_name>
    <description>Lyophilisate and solution for IV use (glass ampoule of lyophilisate + 1 ml glass ampoule of solvent) 6 mg per day Continuous intravenous infusion for 6,5 days</description>
    <arm_group_label>Somatostatin</arm_group_label>
    <other_name>Somatostatine Eumedica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octreotide</intervention_name>
    <description>Solution for SC use 100μg, every 8 hours Subcutaneous injection for 6,5 days</description>
    <arm_group_label>Octreotide</arm_group_label>
    <other_name>Siroctid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women aged 18 years or greater

          -  Signed informed consent

          -  Candidate for pancreaticoduodenectomy or distal pancreatectomy with or without
             splenectomy

        Exclusion Criteria:

          -  Patient with neoadjuvant chemo and/or radiation therapy

          -  Pregnancy

          -  Breastfeeding

          -  Patients with liver disease such as cirrhosis, chronic active hepatitis or chronic
             persistent hepatitis

          -  Patients with abnormal coagulation (INR&gt;1.5) or patients receiving anticoagulants
             that affect PT (prothrombin time) or APTT (activated thromboplastin time)

          -  Patients with WBC &lt;3 X 109/L; PLT &lt;100 X 109/L

          -  Patients who have any current or prior medical condition that may interfere with the
             conduct of the study or the evaluation of its results in the opinion of the
             Investigator

          -  Patients who have participated in any clinical investigation with an investigational
             drug within 1 month prior to inclusion

          -  Known hypersensitivity to somatostatin or somatostatin analogues or any component of
             the somatostatin or octreotide LAR or s.c. formulations

          -  Patient previously treated with somatostatin or somatostatin analogues or any
             component of the somatostatin or octreotide LAR or s.c. formulations

          -  Patients treated by ciclosporin

          -  Patient without health insurance or social security

          -  Patients with a history of non-compliance to medical regimens or who are considered
             potentially unreliable or will be unable to complete the entire study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sébastien GAUJOUX, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cochin Hospital, AP-HP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bertrand DOUSSET, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Cochin Hospital, AP-HP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sébastien GAUJOUX, MD, PhD</last_name>
    <phone>+33 1 58 41 29 61</phone>
    <email>sebastien.gaujoux@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christelle AUGER</last_name>
    <phone>+33 1 58 41 11 86</phone>
    <email>christelle.auger@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sébastien Gaujoux, MD, PhD</last_name>
      <phone>+33 1 58 41 29 61</phone>
      <email>sebastien.gaujoux@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 20, 2016</lastchanged_date>
  <firstreceived_date>December 20, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatectomy</keyword>
  <keyword>Somatostatin analogue</keyword>
  <keyword>Octreotide</keyword>
  <keyword>Pancreatic fistula</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Fistula</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Somatostatin</mesh_term>
    <mesh_term>Octreotide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
